CYTRX CORP
S-1, EX-27.3, 2000-06-21
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CYTRX CORP, S-1, EX-27.2, 2000-06-21
Next: CYTRX CORP, S-1, EX-27.4, 2000-06-21



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<RESTATED>

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       5,895,008
<SECURITIES>                                         0
<RECEIVABLES>                                1,917,013
<ALLOWANCES>                                         0
<INVENTORY>                                  2,272,798
<CURRENT-ASSETS>                            10,113,976
<PP&E>                                       7,367,227
<DEPRECIATION>                             (2,653,641)
<TOTAL-ASSETS>                              24,905,995
<CURRENT-LIABILITIES>                        3,039,118
<BONDS>                                              0
                                0
                                          0
<COMMON>                                         7,986
<OTHER-SE>                                  19,240,409
<TOTAL-LIABILITY-AND-EQUITY>                24,905,995
<SALES>                                        422,039
<TOTAL-REVENUES>                             1,803,345
<CGS>                                                0
<TOTAL-COSTS>                                  242,343
<OTHER-EXPENSES>                             5,886,821
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             293,048
<INCOME-PRETAX>                            (4,618,867)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (4,618,867)
<DISCONTINUED>                             (1,434,125)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (6,052,992)
<EPS-BASIC>                                      (.82)
<EPS-DILUTED>                                    (.82)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission